Intraperitoneal chemotherapy in the management of ovarian cancer

During the past decade, intraperitoneal therapy of ovarian cancer has evolved from a pharmacologic model into an established treatment technique for women with this malignancy. Approximately 40% of patients with small‐volume residual ovarian cancer (microscopic disease or macroscopic tumor, ≤ 0.5 cm...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 1993-02, Vol.71 (S4), p.1565-1570
Main Authors: Markman, Maurie, Reichman, Bonnie, Hakes, Thomas, Curtin, John, Jones, Walter, Lewis, John L., Barakat, Richard, Rubin, Stephen, Mychalczak, Borys, Saigo, Patricia, Almadrones, Lois, Hoskins, William
Format: Article
Language:English
Subjects:
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
cancer chemotherapy
Chemotherapy
cisplatin
Cisplatin - administration & dosage
Female
Forecasting
Humans
Injections, Intraperitoneal
intraperitoneal chemotherapy
Medical sciences
ovarian cancer
Ovarian Neoplasms - drug therapy
Pharmacology. Drug treatments
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:During the past decade, intraperitoneal therapy of ovarian cancer has evolved from a pharmacologic model into an established treatment technique for women with this malignancy. Approximately 40% of patients with small‐volume residual ovarian cancer (microscopic disease or macroscopic tumor, ≤ 0.5 cm in maximum tumor diameter), after an objective response to initial organoplatinum‐based systemic chemotherapy, may have a surgically documented complete response to platinum‐based intraperitoneal chemotherapy. Patients who have not responded to systemic platinum administration rarely will respond to the drug given intraperitoneally, despite the presence of only small‐volume residual disease when this regional treatment strategy is used. Other agents with antineoplastic activity after intraperitoneal administration in women with ovarian cancer include mitoxantrone, taxol, alpha‐interferon and gamma‐interferon, and interleukin‐2. Although intraperitoneal therapy currently is being examined as a component of the initial chemotherapeutic program for patients with ovarian cancer, a precise role for regional drug delivery in this clinical setting remains to be defined.
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.2820710423